Repligen | RGEN - Loan Capital


Repligen reported $551.05M in Loan Capital for its fiscal quarter ending in June of 2026.





Loan Capital Change Date
Agilent USD 3.64B 594M Jun/2026
Align Technology USD 0 0 Dec/2024
Bio Techne USD 200M 60M Mar/2026
BioMarin Pharmaceutical USD 3.53B 2.1B Jun/2026
Bristol-Myers Squibb USD 42.09B 59M Jun/2026
Bruker USD 1.81B 151.8M Jun/2026
Charles River Laboratories USD 2.62B 43.15M Jun/2026
Danaher USD 25.15B 7.59B Jun/2026
Dentsply International USD 2B 10M Jun/2026
General Electric Aerospace USD 17.16B 1.02B Jun/2026
Henry Schein USD 2.3B 27M Jun/2026
Illumina USD 1.49B 1000K Jun/2026
IQVIA Holdings USD 13.7B 284M Jun/2026
Mettler Toledo International USD 2.04B 116.92M Jun/2026
Myriad Genetics USD 120.7M 400K Jun/2026
OraSure Technologies USD 100K 17K Dec/2025
Pacific Biosciences Of California USD 645.38M 223K Dec/2025
Pfizer USD 60.5B 70M Jun/2026
Repligen USD 551.05M 4.46M Jun/2026
Revvity USD 2.63B 1.02M Jun/2026
Standard Biotools USD 299K 0 Mar/2026
Thermo Fisher Scientific USD 39.18B 890M Jun/2026
Waters USD 5.09B 129M Jun/2026
West Pharmaceutical Services USD 202.9M 100K Jun/2026